Envision Pharma Group expands its Market Access communications division

News icon

NEWS ARTICLE

Mar 3, 2015

Envision Pharma Group has expanded its Market Access communications division with two senior appointments in the United States.

Envision Pharma Group has expanded its Market Access communications division with two senior appointments in the United States.
 

William (Bill) Dreitlein, PharmD, BCPS – Portfolio Lead based at Envision’s office in Madison, NJ. Bill leads a talented team of analysts and writers in the US and Europe. Together with our Consultants, they plan and communicate value-related evidence to payers and providers who make patient access decisions. Bill and his team produce a variety of assets, including HEOR publications, systematic literature reviews, value dossiers, health technology assessment submissions, formulary packs, managed markets training decks, and budget impact analyses. .

Bill holds Bachelor of Science and Doctor of Pharmacy degrees from Rutgers University. He spent over 10 years working payer-side at Medco Health Solutions, most recently as Director, Scientific Affairs. He also managed a department of copy writers, medical writers/directors, editors and freelance contributors at a New York based managed markets agency.
 

Karen E. Smoyer, PhD – US Strategic Director based in Maryland. Karen provides specialist consulting and communication expertise in evidence planning and value demonstration. She brings particular strengths in real-world evidence and research design, garnered from both academic and commercial settings.

Karen joins Envision from another medical communications agency, where she led the US Value Demonstration Practice. Karen was previously a research leader at Thomson Reuters and an Outcomes Research Manager at HealthCore, part of Anthem (formerly WellPoint).  She gained her PhD at the University of Minnesota (Minneapolis-St. Paul), before embarking on an academic career at the University of Alberta in Canada.

“We are delighted that Bill and Karen have joined Envision’s value communications practice” said Trevor Fitzpatrick, Division Lead Market Access Solutions. “They each play a strong role in helping end-to-end integration of our clients’ clinical and health-economic communications. We believe this integration is critical in providing the compelling evidence of product value required by payers and providers. Envision offers a unique blend of scientific, HEOR and market access expertise, coupled with our purpose-built technology solutions, to help achieve effective integration and information flow.”

 

 

Envision Pharma Group logo